GSK 3206640A
Alternative Names: GSK Biologicals' influenza vaccine GSK3206640A; GSK-3206640ALatest Information Update: 28 Jul 2018
Price :
$50 *
At a glance
- Originator GlaxoSmithKline Biologicals
- Class Influenza A virus H7N9 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza A virus H7N9 subtype
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for phase-I development in Influenza-A virus H7N9 subtype(Prevention, In volunteers, In adults) in Canada (IM, Injection)
- 28 Jul 2018 No recent reports of development identified for phase-I development in Influenza-A virus H7N9 subtype(Prevention, In volunteers, In adults) in USA (IM, Injection)
- 03 Feb 2015 GlaxoSmithKline completes a phase I trial in Influenza-A virus H7N9 subtype (prevention, in adults, in volunteers) in USA and Canada (NCT01999842)